Advances in the chemoprevention of non-melanoma skin cancer in high-risk organ transplant recipients

Seminars in Oncology

Volumn 39, Issue 2, 2012, Pages 134-138

  Lien, Mary H ^a,b   Fenske, Neil Alan ^a,b   Glass, L Frank ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEXAROTENE; CARBOPLATIN; CHOLESTEROL; CREATINE KINASE; CREATININE; ETRETIN; ETRETINATE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; IMMUNOSUPPRESSIVE AGENT; ISOTRETINOIN; LEVOTHYROXINE; MAGNESIUM; NITROGEN; PACLITAXEL; PHOSPHORUS; PLACEBO; POTASSIUM; PSORALEN; RETINOIC ACID RECEPTOR; RETINOID; SODIUM; SORAFENIB; THYROXINE; TRIACYLGLYCEROL; UREA;

ACNE; ACUTE PANCREATITIS; ALOPECIA; ANKYLOSING HYPEROSTOSIS; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; BRAIN PSEUDOTUMOR; CANCER CHEMOTHERAPY; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; DEMINERALIZATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; DRY LIP; DRY SKIN; ELECTROLYTE DISTURBANCE; EPISTAXIS; FREE THYROXINE INDEX; GENODERMATOSIS; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HYPEROSTOSIS; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KERATOACANTHOMA; KIDNEY TRANSPLANTATION; LIP DISEASE; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; LOW DRUG DOSE; MEDICAL HISTORY; METASTASIS; MUCOCUTANEOUS DRYNESS; MUCOCUTANEOUS XEROSIS; MYALGIA; NAIL DYSTROPHY; NODULOCYSTIC ACNE; ORGAN TRANSPLANTATION; OVARY CANCER; PREGNANT WOMAN; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RHABDOMYOLYSIS; SIDE EFFECT; SKIN CANCER; SKIN EXFOLIATION; SQUAMOUS CELL CARCINOMA; TERATOGENICITY; THYROID DISEASE; THYROID FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; XEROSIS; XEROSTOMIA;

ANIMALS; CARCINOMA, BASAL CELL; CHEMOPREVENTION; DOUBLE-BLIND METHOD; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINOIDS; RISK FACTORS; SKIN NEOPLASMS; TRANSPLANTATION;

EID: 84859401604     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.01.001     Document Type: Article

References (23)

1. L.A. Hansen, C.C. Sigman, F. Andreola Retinoids in chemoprevention and differentiation therapy Carcinogenesis 21 2000 1271 1279
2. R. Schule, P. Rangarajan, N. Yang Retinoic acid is a negative regulator of AP-1-responsive genes Proc Natl Acad Sci USA 88 1991 6092 6096
3. T.I. Wright, J.M. Spencer, F.P. Flowers Chemoprevention of nonmelanoma skin cancer J Am Acad Dermatol 54 2006 933 946
4. C. Marquez, S.M. Bair, E. Smithberger Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients J Drugs Dermatol 9 2010 753 758
5. P. Chambon The retinoid signaling pathway: molecular and genetic analysis Semin Cell Biol 5 1994 115 125
6. G.E. Gibson, A. O'Grady, E.W. Kay Low dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients J Eur Acad Dermatol Venereol 10 1998 42 47
7. B.T. Kovach, H.H. Sams, T. Stasko Systemic strategies for chemoprevention of skin cancers in transplant recipients Clin Transplant 19 2005 726 734
8. I.R. McNamara, J. Muir, A.J. Galbraith Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation J Heart Lung Transplant 21 2002 1201 1205
9. N. Levine, T.E. Moon, B. Cartmel Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial Southwest Skin Cancer Prevention Study Group Cancer Epidemiol Biomarkers Prev 6 1997 957 961
10. D. Shuttleworth, R. Marks, P.J.A. Griffin, J.R. Salaman Treatment of cutaneous neoplasia with etretinate in renal transplant recipients Q J Med 68 1988 717 724
11. J. Bavinck, L. Tieben, F. Van der Woude Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study J Clin Oncol 13 1995 1933 1938
12. D.B. McKenna, G.M. Murphy Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin Br J Dermatol 140 1999 656 660
13. Y. De Graaf, S. Euvrard, J.N. Bavinck Systemic and topical retinoids in the management of skin cancer in organ transplant recipients Dermatol Surg 30 2004 656 661
14. C.A. Harwood, M. Leedham-Green, I.M. Leigh Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study Arch Dermatol 141 2005 456 464
15. C. Otley, T. Staska, W. Tope Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects Dermatol Surg 32 2006 562 568
16. Acitretin [package insert] 2004 Connetics Corp Palo Alto, CA
17. A. Desai, F. Kartono, J.Q. Del Rosso Systemic retinoid therapy: a status report on optimal use and safety of long-term therapy Dermatol Clin 25 2007 185 193
18. K.T. Flaherty, I. Puzanov, K.B. Kim Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 8099
19. C. Assaf, M. Bagot, R. Drummer Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion Br J Dermatol 155 2006 261 266
20. M. Duvic, A.G. Martin, Y. Kim Phase 2 and 3 clinical trial of oral bexarotene (Targretin capusles) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma Arch Dermatol 137 2001 581 593
21. R. Talpur, S. Ward, N. Apisarnthanarax Optimizing bexarotene therapy for cutaneous T-cell lymphoma J Am Acad Dermatol 47 2002 672 684
22. R. Gniadecki, C. Assaf, M. Bagot The optimal use of bexarotene in cutaneous T-cell lymphoma Br J Dermatol 157 2007 433 440
23. M. Duvic, K. Hymes, P. Heald Bexarotene Worldwide Study Group Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results J Clin Oncol 19 2001 2456 2471